Welcome to our dedicated page for Applied Genetic news (Ticker: AGTC), a resource for investors and traders seeking the latest updates and insights on Applied Genetic stock.
The AGTC (Applied Genetic Technologies Corporation) news archive on Stock Titan covers the company’s history as a clinical-stage biotechnology developer of adeno-associated virus (AAV)-based gene therapies for rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. News releases repeatedly describe AGTC’s focus on inherited retinal diseases, with its most advanced clinical programs in X-linked retinitis pigmentosa (XLRP) and achromatopsia due to CNGB3 variants (ACHM CNGB3).
Readers will find detailed coverage of the strategic transaction in which a portfolio company of Syncona Limited agreed to acquire AGTC through a tender offer and subsequent merger. Multiple releases from October through December 2022 outline the tender offer terms, the board’s unanimous recommendation, reminders to shareholders about tender deadlines, and the final confirmation that the acquisition closed and AGTC became an indirect, wholly owned subsidiary of Syncona Limited, with its common stock delisted from the Nasdaq Global Stock Market.
The archive also includes earlier corporate updates, such as announcements about AGTC’s participation in investor conferences and reiterations of its development strategy in AAV-based gene therapy, inherited retinal disease programs, and preclinical work in optogenetics, otology and CNS disorders. In addition, later news from Beacon Therapeutics references laru-zova (laruparetigene zovaparvovec), described in a presentation title as “AGTC-501,” providing continuity for those tracking the historical XLRP program originally developed at AGTC.
Investors, researchers and industry observers can use this news page to review AGTC’s public communications, understand the rationale and structure of the Syncona acquisition, and follow how AGTC’s legacy XLRP asset is referenced in subsequent clinical trial updates from Beacon Therapeutics.
Applied Genetic Technologies Corporation (AGTC), a clinical-stage biotechnology company, announced its participation in several upcoming investor conferences. Key Events include:
- BTIG Biotechnology Conference - August 8, 2022, featuring CFO Jon Lieber.
- Wedbush PacGrow Healthcare Conference - August 9, 2022, with CEO Sue Washer and CFO Jon Lieber.
- H.C. Wainwright 2nd Annual Ophthalmology Conference - August 17, 2022, with an on-demand presentation by Sue Washer.
AGTC focuses on developing gene therapies for inherited retinal diseases and has strategic collaborations in optogenetics and CNS disorders.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced favorable FDA feedback on its manufacturing facility's cGMP design, crucial for its pipeline, particularly X-Linked Retinitis Pigmentosa and Achromatopsia B3 programs. This feedback supports the next construction phase, with initial operations expected in Q4 2022 and GMP capabilities by Q1 2023. The facility is pivotal for upcoming clinical development and commercialization efforts. Positive interim data from AGTC-501 trial also reinforces the potential success in addressing inherited retinal diseases.
Applied Genetic Technologies Corporation (AGTC) announced the pricing of its public offering of 16,666,667 shares of common stock and accompanying warrants at $0.60 per share. The offering is expected to raise approximately $10 million, net of underwriting discounts. The proceeds will fund ongoing clinical trials for X-linked retinitis pigmentosa and Achromatopsia, as well as for preclinical developments and working capital. The offering's close is anticipated around July 15, 2022, pending customary closing conditions.
Applied Genetic Technologies Corporation (AGTC) announced plans for an underwritten public offering of common stock and warrants, subject to market conditions. The offering includes a 30-day option for the underwriter to purchase additional shares. Proceeds will support ongoing clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM), preclinical development, and general corporate needs. The Company continues to leverage its AAV-based gene therapies aimed at treating rare diseases.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced interim safety results from three studies at the American Society of Retina Specialists Annual Meeting, taking place from July 13-16, 2022, in New York City. The presentations focus on Phase 1/2 trials of AGTC-401 and AGTC-402 for achromatopsia and the Phase 2 Skyline trial of AGTC-501 for X-linked retinitis pigmentosa. Key presenters include Dr. Lejla Vajzovic and Dr. Rajiv Anand. AGTC aims to develop gene therapies for rare retinal diseases.
Aurion Biotech has appointed Michael Goldstein, M.D., M.B.A., as president and chief medical officer to advance its corneal endothelial cell therapy development. Dr. Goldstein brings extensive experience as a renowned ophthalmologist and biotech executive, previously serving at Ocular Therapeutix (OCUL) and Applied Genetic Technologies Corp (AGTC). His leadership aims to enhance clinical strategy and operations for a treatment addressing corneal edema caused by endothelial dysfunction. This innovative therapy offers significant advantages over traditional corneal transplants, including a more straightforward procedure and a greater supply of cells from donor corneas.
AGTC announces the appointment of Eduardo Jacobo as Sr. Vice President of GMP Manufacturing and Dr. David Jacobs as Sr. Vice President of Clinical Research and Medical Affairs. Jacobo brings over 30 years of healthcare experience, having previously led GMP gene therapy manufacturing at Sangamo Therapeutics. Dr. Jacobs has over 20 years of experience in biopharmaceutical development, previously overseeing clinical programs at Biogen and Daiichi Sankyo. AGTC aims to enhance its manufacturing capabilities and advance its clinical programs in X-linked retinitis pigmentosa and achromatopsia.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced an encore presentation of interim data from its ongoing Phase 2 Skyline trial of AGTC-501 at the Macula Society Annual Meeting in Berlin. The trial targets mutations in the RPGR gene in patients with X-linked retinitis pigmentosa (XLRP). Interim results indicate significant improvements in visual sensitivity with a favorable safety profile. AGTC aims to advance AGTC-501 towards a potential Biologics License Application (BLA) submission, with future updates expected as the trial progresses.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) has established a Scientific Advisory Board (SAB) to support the development of its Complement Factor H (CFH) program aimed at treating dry age-related macular degeneration (AMD). The SAB consists of leading experts in ophthalmology who will provide guidance as AGTC advances the program through preclinical testing and clinical development. Approximately 16 million individuals in the U.S. are affected by AMD, with dry AMD being the most common form, impacting around 15 million patients.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced that its leadership team, including CEO Sue Washer and CFO Jon Lieber, will present virtually at the H.C. Wainwright Global Investment Conference from May 23 - 26, 2022. The presentation will be available on-demand starting May 24 at 7:00 a.m. ET.
AGTC is focused on developing gene therapies for rare diseases, particularly in ophthalmology. Their clinical trials, including X-linked retinitis pigmentosa and achromatopsia, aim to address significant unmet patient needs.